Branded Generics Market Report 2025 (Global Edition)

Global Branded Generics Market Report 2024 Market Size Split by Product Type Outlook: (Value-Added Branded Generics, Trade (Brand) Named Generics), by Consumption Type Outlook: (Oral, Parenteral, Topi...

Branded Generics Market Report Description

We have various report editions of Branded Generics Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape of the Branded Generics Market

In the Branded Generics market's competitive landscape, numerous key competitors are driving innovation and growth. Players use agreements and cooperation strategies to enhance their production capacities and expand the distribution of their product offerings. This will assist corporations in the creation, manufacture, and distribution of branded generic equivalents.

In June 2024, Cipla Limited and Takeda Pharmaceutical Company announced a non-exclusive patent license agreement for the commercialisation of Vonoprazan in India. Vonoprazan, an oral potassium-competitive acid blocker (P-CAB), is used to treat acid-related disorders, such as Gastroesophageal Reflux Disease (GERD), peptic ulcers, and the eradication of Helicobacter pylori. Vonoprazan will be marketed in India under Cipla's trademark brands, which will address significant medical needs and enhance the quality of life of patients.

(Source:https://www.cipla.com/press-releases-statements/cipla-signs-a-non-exclusive-patent-license-agreement-with-takeda-to-commercialize-vonoprazan-drug-in-india)

In March 2023, the Medicines Patent Pool has entered into sublicense agreements with Aurobindo Pharma, Cipla, and Viatris to produce generic versions of cabotegravir LA, ViiV Healthcare's HIV prevention drug. These generics will be manufactured in India and South Africa and distributed in 90 countries, subject to regulatory approvals, as a result of a 2022 licensing agreement. The initiative's objective is to improve the availability of affordable HIV prevention for at-risk populations, with a particular emphasis on sub-Saharan Africa. ViiV Healthcare will provide manufacturers with technical expertise to facilitate the development and accessibility of the drug.

(Source:https://www.thehindu.com/business/aurobindo-cipla-viatris-to-make-generic-of-viivs-hiv-prevention-drug/article66680473.ece) In June 2022, a portfolio of branded and generic injectable products was acquired by Dr. Reddy's Laboratories from Eton Pharmaceuticals. This portfolio comprises a first-to-file approved ANDA for Cysteine Hydrochloride, as well as Biorphen® (phenylephrine hydrochloride) Injection and Rezipres® (ephedrine hydrochloride) Injection. The acquisition, which is valued at $5 million upfront with up to $45 million in contingent payments, is intended to improve Dr. Reddy's U.S. institutional business by offering critical care products with limited competition. This strategic move is in alignment with Dr. Reddy's objective to address supply concerns in healthcare systems and expand affordable medication access.

(Source:https://www.businesswire.com/news/home/20220624005239/en/Dr.-Reddys-Laboratories-Announces-the-Acquisition-of-an-Injectable-Product-Portfolio-from-Eton-Pharma)

Top Companies Market Share in Branded Generics Industry: (In no particular order of Rank)

• Teva Pharmaceutical Industries Ltd.
• Lupin
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Endo International plc
• GlaxoSmithKline plc
• Pfizer Inc.
• Apotex Inc.
• Viatris Inc.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Branded Generics Market

Which Region Dominates the Branded Generics Market in 2024?

According to Cognitive Market Research, North America currently dominates the Branded Generics market, and the region is expected to have significant growth during the projected period. One of the elements that is driving growth is the somewhat high penetration of branded generic pharmaceuticals. Other considerations include the rising illness burden and the expanding number of elderly people.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). It is anticipated that the main growth drivers would be the increased penetration of goods in nations such as Japan and India. Both of these countries.

The current report Scope analyzes Branded Generics Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Branded Generics

According to Cognitive Market Research, the global Branded Generics market size was estimated at USD 245142.6 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 98057.04 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Branded Generics market with a market size of USD 77367.00 million in 2024 and is projected to grow at a CAGR of 4.0% during the forecast period. The U.S. market's Rising incidence of chronic illnesses and a spike in Abbreviated New Drug Application (ANDA) approvals.
• The Canada Branded Generics market had a market share of USD 11766.84 million in 2024 and is projected to grow at a CAGR of 5.0% during the forecast period. Canada’s Government measures advocating for generic pharmaceuticals and increasing healthcare expenditures.
• The Mexico Branded Generics market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 8923.19 million in 2024.

Europe Branded Generics

According to Cognitive Market Research, the global Branded Generics market size was estimated at USD 245142.6 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 73542.78 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.5% from 2024 to 2031.

• The United Kingdom Branded Generics market had a market share of USD 12355.19 million in 2024 and is projected to grow at a CAGR of 5.3% during the forecast period. In the UK, Branded Generics sales witness an upswing due to the increasing incidence of chronic illnesses.
• The France Branded Generics market is projected to witness growth at a CAGR of 3.7% during the forecast period, with a market size of USD 6765.94 million in 2024.
• According to Cognitive Market Research, the German Branded Generics market size was valued at USD 14561.47 million in 2024 and is projected to grow at a CAGR of 4.7% during the forecast period. In Germany, Branded Generics surged due to the Rising demand for affordable pharmaceuticals and governmental endorsement of generic drugs.
• The Italy Branded Generics market is projected to witness growth at a CAGR of 3.9% during the forecast period, with a market size of USD 6324.68 million in 2024.
• The Russia Branded Generics market is projected to witness growth at a CAGR of 3.5% during the forecast period, with a market size of USD 11399.13 million in 2024.
• The Spain Branded Generics market is projected to witness growth at a CAGR of 3.6% during the forecast period with a market size of USD 6030.51 million in 2024
• The Luxembourg Branded Generics market is projected to witness growth at a CAGR of 4.6% during the forecast period, with a market size of USD 2279.83 million in 2024.
• The Portugal Branded Generics market is projected to witness growth at a CAGR of 4.3% during the forecast period, with a market size of USD 1544.40 million in 2024.
• The Greece Branded Generics market is projected to witness growth at a CAGR of 4.8% during the forecast period, with a market size of USD 882.51 million in 2024.
• The Rest of Europe's Branded Generics market is projected to witness growth at a CAGR of 3.2% during the forecast period, with a market size of USD 11399.13 million in 2024.

Asia Pacific Branded Generics

According to Cognitive Market Research, the global Branded Generics market size was estimated at USD 245142.6 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 56382.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.0% from 2024 to 2031.

• According to Cognitive Market Research, the China Branded Generics market size was valued at USD 25372.26 million in 2024 and is projected to grow at a CAGR of 7.5% during the forecast period. Branded Generics surged in China due to Expanding healthcare infrastructure and rising incidence of chronic illnesses.
• The Japan Branded Generics market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 7780.83 million in 2024.
• The India Branded Generics market had a market share of USD 6765.94 million in 2024 and is projected to grow at a CAGR of 9.8% during the forecast period. India's heightened governmental endorsement for generic medications.
• The South Korean Branded Generics market is projected to witness growth at a CAGR of 7.1% during the forecast period, with a market size of USD 5638.28 million in 2024.
• The Australian Branded Generics market is projected to witness growth at a CAGR of 7.7% during the forecast period, with a market size of USD 2931.91 million in 2024.
• The South East Asia Branded Generics market is projected to witness growth at a CAGR of 9.0% during the forecast period, with a market size of USD 3890.41 million in 2024.
• The Rest of Asia Pacific Branded Generics market is projected to witness growth at a CAGR of 7.8% during the forecast period, with a market size of USD 4003.18 million in 2024.

South America Branded Generics

According to Cognitive Market Research, the global Branded Generics market size was estimated at USD 245142.6 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 12257.13 million 2024 and will grow at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Branded Generics market size was valued at USD 5246.05 million in 2024 and is projected to grow at a CAGR of 6.0% during the forecast period. Branded Generics flourished in Brazil due to Escalating incidence of chronic illnesses and expanding governmental efforts to advocate for generic products.
• Argentina's Branded Generics market had a market share of USD 2059.20 million in 2024 and is projected to grow at a CAGR of 6.3% during the forecast period. Argentina's Rising healthcare expenditures and expanding market share of branded generic pharmaceuticals.
• Colombia Branded Generics market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD 1090.88 million in 2024.
• Peru Branded Generics market is projected to witness growth at a CAGR of 5.6% during the forecast period, with a market size of USD 1005.08 million in 2024.
• Chile Branded Generics market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 882.51 million in 2024.
• The Rest of Latin America's Branded Generics market is projected to witness growth at a CAGR of 4.5% during the forecast period, with a market size of USD 1973.40 million in 2024.

Middle East and Africa Branded Generics

According to Cognitive Market Research, the global Branded Generics market size was estimated at USD 245142.6 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 4902.85 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031..

• The GCC Countries Branded Generics market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 2098.42 million in 2024. Branded Generics sales flourish due to the Increasing incidence of chronic illnesses and governmental efforts to encourage the use of generic pharmaceuticals.
• The Egypt Branded Generics market is projected to witness growth at a CAGR of 6.0% during the forecast period, with a market size of USD 514.80 million in 2024.
• The South Africa Branded Generics market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 774.65 million in 2024. Branded Generics sales flourished in South Africa due to Rising demand for affordable pharmaceuticals and escalating healthcare expenses.
• The Turkey Branded Generics market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD 421.65 million in 2024.
• The Nigeria Branded Generics market is projected to witness growth at a CAGR of 4.8% during the forecast period, with a market size of USD 514.80 million in 2024.
• The Rest of the MEA Branded Generics market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD 578.54 million in 2024.

Branded Generics Market Analysis

How are Segments Performing in the Global Branded Generics Market?

Branded Generics Market Product Type Segment Analysis

According to Cognitive Market Research, Value-Added Branded Generics are likely to dominate the Branded Generics Market over the forecast period. These medicines give supplementary advantages compared to typical generics, including superior formulations, increased patient adherence, and higher therapeutic results, making them more appealing to both healthcare professionals and patients.

The Trade (Brand) Named Generics is the fastest-growing segment in the Branded Generics Market. This expansion is propelled by the rising frequency of patent expirations, enabling manufacturers to make and sell generics under a brand name, so offering a competitive advantage and enhanced profit margins.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Branded Generics Industry. Request a Free Sample PDF!

Branded Generics Market Consumption Type Segment Analysis

According to Cognitive Market Research, the oral formulation segment holds the largest share of the market. This is because oral drugs are simple to administer, patients are more likely to participate in their treatment, and they cover a broad variety of therapeutic uses.

In the Branded Generics Market, the parenteral formulation sector has been expanding at a rapid pace. Increasing demand for injectable drugs, which provide immediate therapeutic effects and are necessary for treatments that need precise dosage, is the primary factor driving this development.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Branded Generics Drug Class Outlook: Segment Analysis

Branded Generics Market Drug Class Segment Analysis

According to Cognitive Market Research, The Antihypertensive drugs segment holds the largest market share. This is a result of the significant incidence of hypertension around the world and the ongoing need for treatment choices that are within reasonable price ranges.

In the Branded Generics market, the rapidly growing sector is the Hormones category. The growth in this category is because of the increasing expenditures being made to produce complicated generics or value-added generics. There has been a rise in the incidence of metabolic illnesses as a result of an increase in the prevalence of sedentary lifestyles. An imbalance of the thyroid and sexual hormones is included among these illnesses.

• Alkylating Agents
• Antimetabolites
• Hormones
• Anti-Hypertensive
• Lipid Lowering Drugs
• Anti-Depressants
• Anti-Psychotics
• Anti-Epileptic
• Others

Branded Generics Distribution Channel Outlook: Segment Analysis

Branded Generics Market Distribution Channel Segment Analysis

According to Cognitive Market Research, the Retail Pharmacies segment dominates the market. This is because of their ubiquitous presence, the ease with which they can be accessed, and the convenience that they provide to customers who come to purchase pharmaceuticals.

Online Pharmacies are projected to be the fastest-growing segment in the Branded Generics market. The growing acceptance of digital platforms is driving the rise, the convenience of home delivery and the rising penetration of the internet, which enables people to access and buy drugs via the internet conveniently.

• Alkylating Agents
• Antimetabolites
• Hormones
• Anti-Hypertensive
• Lipid Lowering Drugs
• Anti-Depressants
• Anti-Psychotics
• Anti-Epileptic
• Others

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion